Verrica Pharmaceuticals Future Growth
Future criteria checks 2/6
Verrica Pharmaceuticals is forecast to grow earnings and revenue by 57.7% and 45% per annum respectively while EPS is expected to grow by 61.5% per annum.
Key information
57.7%
Earnings growth rate
61.5%
EPS growth rate
| Pharmaceuticals earnings growth | 19.7% |
| Revenue growth rate | 45.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 20 Dec 2024 |
Recent future growth updates
Recent updates
The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%
Oct 03
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 17With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For
Aug 16Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jul 21Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jan 11Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation
Jun 28We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely
Feb 05Vectoring Back In On Verrica Pharmaceuticals
Aug 31Verrica Pharmaceuticals reports insider buying
Jul 06Verrica Pharmaceuticals stock slides on proposed share offering
Jun 29Verrica Pharmaceuticals Should Receive Second CRL Today
May 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 65 | 1 | 86 | 139 | 3 |
| 12/31/2026 | 37 | -27 | 16 | 55 | 4 |
| 12/31/2025 | 15 | -42 | -28 | -14 | 4 |
| 12/31/2024 | 8 | -73 | -62 | -61 | 4 |
| 9/30/2024 | 9 | -85 | -60 | -59 | N/A |
| 6/30/2024 | 14 | -87 | -66 | -66 | N/A |
| 3/31/2024 | 9 | -81 | -54 | -54 | N/A |
| 12/31/2023 | 5 | -67 | -39 | -39 | N/A |
| 9/30/2023 | 3 | -48 | -29 | -29 | N/A |
| 6/30/2023 | 9 | -23 | -13 | -12 | N/A |
| 3/31/2023 | 9 | -23 | -15 | -15 | N/A |
| 12/31/2022 | 9 | -24 | -19 | -19 | N/A |
| 9/30/2022 | 9 | -28 | -23 | -22 | N/A |
| 6/30/2022 | 1 | -41 | -35 | -35 | N/A |
| 3/31/2022 | 0 | -43 | -26 | -25 | N/A |
| 12/31/2021 | 12 | -35 | -28 | -28 | N/A |
| 9/30/2021 | 12 | -39 | -26 | -25 | N/A |
| 6/30/2021 | 12 | -36 | -23 | -22 | N/A |
| 3/31/2021 | 12 | -34 | -34 | -33 | N/A |
| 12/31/2020 | N/A | -43 | -32 | -30 | N/A |
| 9/30/2020 | N/A | -37 | -33 | -32 | N/A |
| 6/30/2020 | N/A | -33 | -33 | -32 | N/A |
| 3/31/2020 | N/A | -31 | -30 | -28 | N/A |
| 12/31/2019 | N/A | -28 | -28 | -27 | N/A |
| 9/30/2019 | N/A | -28 | -27 | -26 | N/A |
| 6/30/2019 | N/A | -28 | -25 | -24 | N/A |
| 3/31/2019 | N/A | -26 | -23 | -23 | N/A |
| 12/31/2018 | N/A | -21 | -19 | -18 | N/A |
| 9/30/2018 | N/A | -20 | -13 | -13 | N/A |
| 6/30/2018 | N/A | -15 | N/A | -9 | N/A |
| 3/31/2018 | N/A | -11 | N/A | -6 | N/A |
| 12/31/2017 | N/A | -10 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VRCA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VRCA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VRCA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VRCA's revenue (45% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: VRCA's revenue (45% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VRCA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 00:56 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Verrica Pharmaceuticals Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Oren Livnat | H.C. Wainwright & Co. |